Blog

Jun 2023

Boosting Oncology Care with Decentralized Clinical Trials

By |2023-06-06T15:11:23+02:00June 4, 2023|Blog, News|0 Comments

Discover how Decentralized Clinical Trials (DCTs) have the potential to reshape oncology care. Using our eyesON DCT Outlook, we reveal how patient demographics, broadband internet, and registered oncologists could drive DCT opportunities and potentially enhance cancer survivorship.

May 2023

Training Implications of the ICH E6(R3) and E8(R1) Guidelines

By |2024-09-11T16:49:40+02:00May 29, 2023|Blog, Good Clinical Practice, News|0 Comments

Be prepared for ICH E6(R3): turn guidelines into real-world action. In this post, we delve into the key updates and training gaps.

May 2023

A Comparative Review of the ICH E6(R3) and E8(R1) Guidelines

By |2024-09-11T16:55:48+02:00May 26, 2023|Blog, Good Clinical Practice, News|Comments Off on A Comparative Review of the ICH E6(R3) and E8(R1) Guidelines

Unpacking the new ICH guidelines, E6(R3) and E8(R1), we illuminate their key elements, identify gaps, and compare the two in terms of their unity, differences, and complementarity.

May 2023

Embracing the Future: FDA’s New Draft Guidance on Decentralized Clinical Trials

By |2023-05-12T17:33:36+02:00May 12, 2023|Blog, News|Comments Off on Embracing the Future: FDA’s New Draft Guidance on Decentralized Clinical Trials

Dive into the FDA's latest draft guidance on Decentralized Clinical Trials and the role of Risk-Based Quality Management. Learn how RBQM and centralized monitoring can elevate your clinical research efficiency and reliability.

May 2023

Big Pharma M&As: Is It Worth the Trouble?

By |2024-06-07T14:30:31+02:00May 10, 2023|Blog, M&A Insights and Solutions, News|Comments Off on Big Pharma M&As: Is It Worth the Trouble?

Big Pharma M&As: A Worthwhile Challenge? Navigating the complex landscape of M&As in the pharmaceutical industry comes with unique objectives and potential benefits. But do these transactions truly drive shareholder value for the acquiring firm?

May 2023

Enhancing R&D Due Diligence in Pharma M&As: The Role of MyRBQM Portal

By |2024-06-07T15:19:19+02:00May 10, 2023|Blog, M&A Insights and Solutions, News|Comments Off on Enhancing R&D Due Diligence in Pharma M&As: The Role of MyRBQM Portal

Navigate your M&A journey confidently with Cyntegrity's MyRBQM Portal. Aspiring to hit your targets within 6-12 months? Discover how we can make it possible in R&D due diligence.

Apr 2023

Global Impact of COVID-19 Pandemic on Clinical Trials

By |2023-04-20T12:38:49+02:00April 19, 2023|Blog, News|Comments Off on Global Impact of COVID-19 Pandemic on Clinical Trials

Wondering how the COVID-19 pandemic has impacted clinical trials worldwide? The COVID-19 pandemic has brought unprecedented challenges to the healthcare industry worldwide. The clinical trial sector has been no exception, and it has undergone significant changes over the past few years. From the [...]

Mar 2023

Synergy of QbD, RBM, and RBQM in Trials

By |2024-06-14T17:44:33+02:00March 20, 2023|Blog, News|Comments Off on Synergy of QbD, RBM, and RBQM in Trials

Clinical trials require a comprehensive approach to ensure quality and efficiency. Quality by Design, Risk-Based Monitoring, and Risk-Based Quality Management work together to achieve these goals, focusing on building quality into the trial process, targeting monitoring activities, and continuously improving trial quality.

Go to Top